Oblique Therapeutics AB, raises 98 MSEK in a private placement investment round.
Oblique Therapeutics and Targovax enter collaboration to target mutant RAS cancers by combining their ONCOS and Abiprot™ platforms
Oblique Therapeutics AB has identified a potentially important epitope for generation of SARS-CoV-2 antibodies
General Meeting 2020
Notice convening the Extraordinary General Meeting on December 6 at 2pm
We are proud to have been recognised by StartUp City Magazine as one of the most promising European Biotech startups in 2019!
We welcome our new owners
New collaboration with Pharma